Evolus EOLS In-process research and development
Discontinued — last reported Q4 '25
In-process research and development at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Evolus in its filing.
Tagged under the XBRL concept eols:ResearchAndDevelopmentInProcess1.
The official record: Evolus’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Evolus's in-process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Evolus's in-process research and development?
- Evolus (EOLS) reported in-process research and development of $0 in Q4 2025.
- What is the long-term trend for Evolus's in-process research and development?
- Over 2 years (2023 to 2025), Evolus's in-process research and development has grown at a -100.0% compound annual growth rate (CAGR), from $8.87M to $0.
- What does in-process research and development mean?
- This metric represents the costs associated with research and development activities for projects that have not yet reached technological feasibility or commercialization. It reflects the company's investment in future product pipelines and innovation within the aesthetic medical market. Tracking this helps investors assess the long-term growth potential and the commitment to expanding the product portfolio.